Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Urologic oncology

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.urolonc.2015.01.017PMID 25726498
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.

  2014cited by this paper
• Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer

  2014influential reference
• Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer.

  2014cited by this paper
• Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.

  2014cited by this paper
• Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate.

  2013cited by this paper
• Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies (2d HT) in metastatic castration-resistant prostate cancer (mCRPC).

  2013cited by this paper
• Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter.

  2013cited by this paper
• Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

  2013cited by this paper
• Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.

  2013cited by this paper
• Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer

  2012influential reference
• Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel.

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy

  2011cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Cancer esearch apeutics , Targets , and Chemical Biology ulin-Targeting Chemotherapy Impairs Androgen R eptor Activity in Prostate Cancer

  2010cited by this paper
• Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

  2010cited by this paper
• Docetaxel down‐regulates the expression of androgen receptor and prostate‐specific antigen but not prostate‐specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy

  2009influential reference
• Experimental Therapeutics , Molecular Targets , and Chemical Biology Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer

  2009cited by this paper
• Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.

  2009influential reference
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008cited by this paper
• Time to an undetectable prostate‐specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer‐specific mortality

  2007influential reference
• Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

  2005cited by this paper
• The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

  2005cited by this paper
• Prognosis after androgen deprivation therapy in men with a rising PSA after prostatectomy

  2005influential reference
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Nadir prostate‐specific antigen best predicts the progression to androgen‐independent prostate cancer

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

  2004cited by this paper
• Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.

  2002influential reference
• AJCC Cancer Staging Manual

  2002cited by this paper
• Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.

  2002influential reference
• Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

  2002cited by this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999influential reference
• A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies.

  1999influential reference
• Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

  1998cited by this paper
• The dynamics of prostate specific antigen in hormone refractory prostate carcinoma

  1998cited by this paper
• Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council.

  1996cited by this paper
• Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

  1993influential reference
• Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment.

  1992cited by this paper
• Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone‐refractory prostatic cancer treated with single‐agent chemotherapy

  1992influential reference
• Prognostic factors in patients with advanced stage prostate cancer.

  1985cited by this paper
• Urologic pathology: The prostate

  1977cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper

• Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

  2023cites this paper
• Dynamic changes in PSA levels predict prognostic outcomes in prostate cancer patients undergoing androgen -deprivation therapy: A multicenter retrospective analysis

  2023cites this paper
• Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer

  2022cites this paper
• Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer

  2022cites this paper
• Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics.

  2021cites this paper
• Prostate Neoplasm

  2019cites this paper
• Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer

  2019cites this paper
• Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer

  2019cites this paper
• PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China

  2017cites this paper
• Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

  2017cites this paper
• Factores asociados con la respuesta a la terapia de privación androgénica en pacientes con cáncer de próstata y metástasis óseas en una institución

  2016cites this paper